title: The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
abstract: OBJECTIVE
  Low-grade endometrial stromal sarcoma (EES) is a rare tumour with a high recurrence rate but a very good prognosis. Responses to hormonal treatment of these recurrences have been published in case reports. The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
  
  
  METHODS
  Thirteen consecutive patients with residual or recurrent disease were retrieved from the files. Eleven patients with measurable disease were treated with hormones and form the basis of this study. The following data were collected: age, date of primary diagnosis, type of primary treatment, the presence and localization of residual or recurrent disease, type of treatment, response, duration of response and survival.
  
  
  RESULTS
  After hormonal treatment 9 (82%) patients showed an objective response (4 complete response; 5 partial response), one showed stable disease (26+ months) and one progressive disease. Response duration was from 4+ to 252+ months (median 48+ months).
  
  
  CONCLUSIONS
  Hormonal treatment for measurable residual or recurrent low-grade ESS has a high response rate and should be considered as the treatment of choice for patients in which recurrent disease cannot easily be resected.
authors.affiliation: Department of Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: Taghride
authors.initials: T
authors.lastname: Dahhan
authors.forename: Guus
authors.initials: G
authors.lastname: Fons
authors.forename: Marrije R
authors.initials: MR
authors.lastname: Buist
authors.forename: Fibo J W
authors.initials: FJ
authors.lastname: Ten Kate
authors.forename: Jacobus
authors.initials: J
authors.lastname: van der Velden
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D000077289:Letrozole; D019290:Megestrol Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D055502:Secondary Prevention; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D011372:Progestins; D014230:Triazoles; D000077289:Letrozole; D019290:Megestrol Acetate